1Corsini A, Arnaboldi L, Raiteri M. Effect of the new HMG-CoA reductase inhibitor cerivastatin on the migration, proliferation and cholesterol synthesis in arterial myocytes. Pharmacol Res, 1996, 33(1): 55-61.
2Grandy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med, 1988, 319: 24-33.
3Egros F, Langan J, Bertolini G, ct al. A one year comparing atorvastatin and pravastatin in patients with hypercholesterolerolemia. Copenhagen:Danish National Press, 1996: 13-15.
4Davidson M, MeKenny J, Stein E, et al. Comparison of one year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol, 1997, 79( 11 ) : 1475.
5Bakker-Arkema R, Fayyad R, Davidson M,et al. One year study comparing the safety and efficacy of atorvastatin to that of lovastatin. Copenhagen:Danish National Press, 1996: 32-35.
6Bcrtolini S, Bittolo BG, Cambell LM, et al. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis, 1997, 130(2): 191.
7Wagner B, Huwel D, Rehorst D, et al. A one year treat-to-tar get study of atorvastatin versus pravastatin in risk-stratified hypercholesterolemia patients. Copenhagen:Danish National Press 1996: 121.
8Dart A, Jerums G, Nicholson G, et al. A multicenter,doubleblind, one year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol, 1997, 80(1): 39.
